442 related articles for article (PubMed ID: 8704175)
1. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
[TBL] [Abstract][Full Text] [Related]
2. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.
Bowne WB; Wolchok JD; Hawkins WG; Srinivasan R; Gregor P; Blachere NE; Moroi Y; Engelhorn ME; Houghton AN; Lewis JJ
Cytokines Cell Mol Ther; 1999 Dec; 5(4):217-25. PubMed ID: 10850386
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
4. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor.
McNeel DG; Schiffman K; Disis ML
Blood; 1999 Apr; 93(8):2653-9. PubMed ID: 10194445
[TBL] [Abstract][Full Text] [Related]
5. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.
Disis ML; Rinn K; Knutson KL; Davis D; Caron D; dela Rosa C; Schiffman K
Blood; 2002 Apr; 99(8):2845-50. PubMed ID: 11929774
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses.
Somani J; Lonial S; Rosenthal H; Resnick S; Kakhniashvili I; Waller EK
Vaccine; 2002 Dec; 21(3-4):221-30. PubMed ID: 12450697
[TBL] [Abstract][Full Text] [Related]
7. Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes.
Kass E; Parker J; Schlom J; Greiner JW
Cytokine; 2000 Jul; 12(7):960-71. PubMed ID: 10880241
[TBL] [Abstract][Full Text] [Related]
8. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
Kwak LW; Young HA; Pennington RW; Weeks SD
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
11. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
Harris RC; Chianese-Bullock KA; Petroni GR; Schaefer JT; Brill LB; Molhoek KR; Deacon DH; Patterson JW; Slingluff CL
J Immunother; 2012 Jan; 35(1):78-88. PubMed ID: 22130163
[TBL] [Abstract][Full Text] [Related]
12. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
14. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens.
Disis ML; Shiota FM; McNeel DG; Knutson KL
Immunobiology; 2003; 207(3):179-86. PubMed ID: 12777059
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
Liu HM; Newbrough SE; Bhatia SK; Dahle CE; Krieg AM; Weiner GJ
Blood; 1998 Nov; 92(10):3730-6. PubMed ID: 9808567
[TBL] [Abstract][Full Text] [Related]
16. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
17. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor.
Neidhart J; Allen KO; Barlow DL; Carpenter M; Shaw DR; Triozzi PL; Conry RM
Vaccine; 2004 Jan; 22(5-6):773-80. PubMed ID: 14741172
[TBL] [Abstract][Full Text] [Related]
18. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
19. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
Front Immunol; 2018; 9():3119. PubMed ID: 30687323
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients.
Verkade MA; van de Wetering J; Klepper M; Vaessen LM; Weimar W; Betjes MG
Kidney Int; 2004 Aug; 66(2):614-21. PubMed ID: 15253714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
